Hurley Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Hurley Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25	Hold	1	–	–	﹤0.01%	659
2025 Q4	$23	Hold	1	–	–	﹤0.01%	587
2025 Q3	$20	Hold	1	–	–	﹤0.01%	686
2025 Q2	$22	Hold	1	–	–	﹤0.01%	461
2025 Q1	$24	Hold	1	–	–	﹤0.01%	497
2024 Q4	$21	Buy	+1	New	+$21	﹤0.01%	402

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Hurley Capital's CPRX Position: Q1 2026 in Review

Hurley Capital held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 1 share worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #659.

Hurley Capital first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Hurley Capital held 1 share of Catalyst Pharmaceutical worth $25 as of Q1 2026.
Hurley Capital left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #659 holding.
Hurley Capital first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.